Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.73 |
| ▸ | BLM | P54132 | 2/20 | 0.71 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.71 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | MMP1 | P03956 | 1/20 | 0.54 |
| ▸ | BCHE | P06276 | 2/20 | 0.53 |
| ▸ | TYR | P14679 | 2/20 | 0.53 |
| ▸ | ACHE | P22303 | 2/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | PPARD | Q03181 | 1/20 | 0.51 |
| ▸ | PPARA | Q07869 | 1/20 | 0.51 |
| ▸ | STAT3 | P40763 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | FOS | P01100 | 1/20 | 0.49 |
| ▸ | TTR | P02766 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31254086 | 1.00 | TSHR (1.00) | TSHRCYP3A4NFKB1BLMPMP22 | |
| SCHEMBL29776919 | 1.00 | TSHR (1.00) | TSHRCYP3A4NFKB1BLMPMP22 | |
| SCHEMBL31254076 | 1.00 | TSHR (1.00) | TSHRCYP3A4NFKB1BLMPMP22 | |
| SCHEMBL31364250 | 1.00 | TSHR (1.00) | TSHRCYP3A4NFKB1BLMPMP22 | |
| Sulfuric Acid SCHEMBL31254117 | 0.92 | TSHR (0.85) | TSHRCYP3A4NFKB1BLMPMP22 | |
| Sulfuric Acid SCHEMBL31006937 | 0.92 | TSHR (0.85) | TSHRCYP3A4NFKB1BLMPMP22 | |
| Sulfuric Acid SCHEMBL11041301 | 0.92 | TSHR (0.85) | TSHRCYP3A4NFKB1BLMPMP22 | |
| Piperazine SCHEMBL31187001 | 0.91 | CYP3A4 (0.82) | TSHRCYP3A4NFKB1BLMPMP22 | |
| SCHEMBL8082807 | 0.87 | TSHR (0.77) | TSHRCYP3A4NFKB1BLMPMP22 | |
| SCHEMBL29761292 | 0.87 | TSHR (0.77) | TSHRCYP3A4NFKB1BLMPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 746 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260002951-A1 | METHOD FOR PROVIDING INFORMATION FOR BRAIN DOPING DIAGNOSIS | KOREA INST SCI & TECH (KR) | 2026-01-01 | — | — | US | claimed |
| US-20250304940-A1 | PROGRAMMABLE ADENINE BASE EDITOR AND USES THEREOF | HUIDAGENE THERAPEUTICS (SINGAPORE) PTE. LTD. (SG) | 2025-10-02 | — | — | US | claimed |
| CN-119985745-A | Detection method for micromolecular phenolic substances and application thereof | 北京中医药大学 | 2025-05-13 | — | — | CN | claimed |
| EP-4522738-A1 | PROGRAMMABLE ADENINE BASE EDITOR AND USES THEREOF | Huidagene Therapeutics (Singapore) Pte. Ltd. (SG) | 2025-03-19 | — | — | EP | claimed |
| CN-119630788-A | Programmable adenine base editor and use thereof | 辉大(上海)生物科技有限公司 | 2025-03-14 | — | — | CN | claimed |
| US-20250009655-A1 | BIPHASIC COMPOSITIONS COMPRISING ONE OR BOTH OF CARBONATE AND PHOSPHATE | Natural Extraction Systems, LLC | 2025-01-09 | — | — | US | claimed |
| CN-119104708-A | Application of kynurenine, formyl-5-hydroxykynurenine and 3-methoxy-4-hydroxyphenylethylene glycol as serum biomarker for evaluating curative effect of Crohn disease | 济南微生态生物医学省实验室 | 2024-12-10 | — | — | CN | claimed |
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| CN-118688315-A | Multichannel high-coverage synchronous quantification method for amino-containing and hydroxyl-containing compounds | 复旦大学 | 2024-09-24 | — | — | CN | claimed |
| CN-116445463-B | Novel plant base editor pAYBEs | 中国农业科学院作物科学研究所 | 2024-06-14 | — | — | CN | claimed |
| WO-2007119004-A2 | METHOD FOR DIAGNOSING IN VITRO OR EX VIVO PSYCHIATRIC DISORDERS AND/OR INTESTINAL DYSBIOSES | AURE (FR) | 2007-10-25 | — | — | WO | claimed |
| EP-1328261-A2 | TREATMENT OF NEURODEGENERATIVE DISEASE | Minerva Biotechnologies Corporation (US) | 2003-07-23 | — | — | EP | claimed |
| US-20030060487-A1 | Treatment of neurodegenerative disease | MINERVA BIOTECHNOLOGIES CORPORATION | 2003-03-27 | — | — | US | claimed |
| WO-2001078709-A2 | TREATMENT OF NEURODEGENERATIVE DISEASE | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2001-10-25 | — | — | WO | claimed |
| EP-0746986-B1 | Delayed release flavourant compositions | GIVAUDAN ROURE INT (CH) | 2000-08-23 | — | — | EP | claimed |
| US-5227472-A | Antigen for producing an antibody against MHPG | DAIICHI RADIOISOTOPE LABORATORIES, LTD. (JP) | 1993-07-13 | — | — | US | claimed |
| US-5145791-A | Immunology | ABBOTT LABORATORIES (US) | 1992-09-08 | — | — | US | claimed |
| EP-0252405-A2 | 3-methoxy-4-hydroxyphenylglycol fluorescence polarization immunoassay | ABBOTT LABORATORIES (US) | 1988-01-13 | — | — | EP | claimed |
| US-4311790-A | SOLVENT EXTRACTION | THE UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 1982-01-19 | — | — | US | claimed |
| US-4259947-A | ISOTOPICALLY LABELED COMPOUNDS | KOBRINSKY PETER C | 1981-04-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060487-A1 | Treatment of neurodegenerative disease | HTT, IAPP, APP | TSHR 4189/4885CYP3A4 4876/4885NFKB1 3132/4885 |
| US-20260002951-A1 | METHOD FOR PROVIDING INFORMATION FOR BRAIN DOPING DIAGNOSIS | COMT, HNMT, PNMT | TSHR 1190/4885CYP3A4 464/4885NFKB1 4862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.